Cortical activity during olfactory stimulation in multiple chemical sensitivity: a (18)F-FDG PET/CT study

Agostino Chiaravalloti, Marco Pagani, Alessandro Micarelli, Barbara Di Pietro, Giuseppe Genovesi, Marco Alessandrini, Orazio Schillaci, Agostino Chiaravalloti, Marco Pagani, Alessandro Micarelli, Barbara Di Pietro, Giuseppe Genovesi, Marco Alessandrini, Orazio Schillaci

Abstract

Purpose: To investigate the differences in brain glucose consumption during olfactory stimulation between subjects affected by multiple chemical sensitivity (MCS) and a group of healthy individuals.

Methods: Two (18)F-FDG PET/CT scans were performed in 26 subjects (6 men and 20 women; mean age 46.7 ± 11 years) with a clinical diagnosis of MCS and in 11 healthy controls (6 women and 5 men; mean age 45.7 ± 11 years), the first scan after a neutral olfactory stimulation (NS) and the second after a pure olfactory stimulation (OS). Differences in (18)F-FDG uptake were analysed by statistical parametric mapping (SPM2).

Results: In controls OS led to an increase in glucose consumption in BA 18 and 19 and a reduction in glucose metabolism in BA 10, 11, 32 and 47. In MCS subjects, OS led to an increase in glucose consumption in BA 20, 23, 18 and 37 and a reduction in glucose metabolism in BA 8, 9 and 10.

Conclusion: The results of our study suggest that cortical activity in subjects with MCS differs from that in healthy individuals during olfactory stimulation.

References

    1. Cancer Biother Radiopharm. 2010 Dec;25(6):665-9
    1. Soc Cogn Affect Neurosci. 2009 Dec;4(4):417-22
    1. PLoS One. 2013;8(3):e57596
    1. Occup Med. 1987 Oct-Dec;2(4):655-61
    1. Rhinology. 1996 Dec;34(4):222-6
    1. Cereb Cortex. 2009 Jan;19(1):66-71
    1. J Psychosom Res. 2014 Nov;77(5):401-8
    1. J Cereb Blood Flow Metab. 1991 Jan;11(1):10-24
    1. J Neurol Sci. 2009 Dec 15;287(1-2):72-8
    1. J Neurophysiol. 1996 May;75(5):1982-96
    1. Int Arch Occup Environ Health. 2008 Jul;81(7):881-7
    1. Int J Immunopathol Pharmacol. 2013 Oct-Dec;26(4):1019-25
    1. Hum Brain Mapp. 2007 Mar;28(3):172-82
    1. J Neurosci. 2000 Oct 15;20(20):7752-9
    1. J Neurochem. 1977 May;28(5):897-916
    1. Chem Senses. 2011 Sep;36(7):641-8
    1. Brain Res Brain Res Rev. 2005 Dec 15;50(2):287-304
    1. Biol Psychol. 2013 Feb;92 (2):135-41
    1. J Cogn Neurosci. 2008 Oct;20(10 ):1815-26
    1. PLoS One. 2013 Nov 21;8(11):e80567
    1. Neuropsychologia. 2013 Jan;51(1):123-31
    1. Brain. 2003 Sep;126(Pt 9):2093-107
    1. Psychol Med. 2002 Nov;32(8):1387-94
    1. Sci Rep. 2014 Jun 03;4:5146
    1. J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):510-4
    1. Nature. 2001 Sep 13;413(6852):211-8
    1. Neuroscientist. 2002 Jun;8(3):204-11
    1. Psychoneuroendocrinology. 2014 Feb;40:140-50
    1. Nature. 1992 Nov 26;360(6402):339-40
    1. Eur J Neurosci. 2003 Aug;18(3):695-703
    1. Hum Brain Mapp. 2009 Aug;30(8):2571-80
    1. Indian J Psychiatry. 2008 Jul;50(3):202-8
    1. J Comp Neurol. 1994 Aug 15;346(3):403-34
    1. Ann Neurol. 2001 Apr;49(4):433-42
    1. Brain Res. 1994 Oct 3;659(1-2):263-6

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere